Sector revisions Genmab A/S Nasdaq

Stocks

Market Closed - Nasdaq Other stock markets 21:00:00 12/06/2026 BST			5-day change	1st Jan Change
25.08 ^USD	-0.63%		-0.28%	-18.57%

06-11	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
06-11	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Visibility	Nbr of analysts
ARGENX SE		15
WUXI APPTEC CO., LTD.		16
BIONTECH SE		19
INSMED INCORPORATED		21
WUXI BIOLOGICS (CAYMAN) INC.		22
EXELIXIS, INC.		16
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.		17
PHARMAESSENTIA CORPORATION		6
MADRIGAL PHARMACEUTICALS, INC.		14
ARROWHEAD PHARMACEUTICALS, INC.		12
AKESO, INC.		20
SUMMIT THERAPEUTICS INC.		13
NUVALENT, INC.		16
CYTOKINETICS, INCORPORATED		20
IMMUNITYBIO, INC.		3
REMEGEN CO., LTD.		14
SAMSUNG EPIS HOLDINGS CO., LTD.	-	1
BIOCON LIMITED		20
Average		15
Weighted average by Cap.		16